Literature DB >> 11385619

Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.

L Dorrell1, B E Willcox, E Y Jones, G Gillespie, H Njai, S Sabally, A Jaye, K DeGleria, T Rostron, E Lepin, A McMichael, H Whittle, S Rowland-Jones.   

Abstract

Human immunodeficiency virus type-1 (HIV-1) cytotoxic T lymphocyte (CTL) epitopes have largely been defined in Caucasian populations infected with clade B virus. Identification of potentially protective CTL epitopes in non-B clade-infected African subjects is important for vaccine development. In a study of CTL responses in clade A-infected Gambians, using cytotoxicity, interferon-gamma (IFN-gamma) enzyme-linked immunospot (ELISpot) and HLA-B53-peptide tetramer assays, we identified three HLA-B53-restricted epitopes in HIV-1 gag p24. CTL specific for an epitope in a highly immunogenic region of the p24 protein showed no cross-reactivity to other HIV-1 clades. Two of the epitopes would not have been predicted from the peptide-binding motif due to the absence of a proline anchor at position 2. Structural analysis of HLA-B53 and its relative, HLA B35, enabled us to re-define the peptide-binding motif to include other P2 anchors. These results demonstrate the value of combined immunological and structural analyses in defining novel CTL epitopes and have implications for HIV-1 vaccine design.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11385619     DOI: 10.1002/1521-4141(200106)31:6<1747::aid-immu1747>3.0.co;2-l

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

2.  Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response.

Authors:  Christof Geldmacher; Ian S Metzler; Sodsai Tovanabutra; Tedi E Asher; Emma Gostick; David R Ambrozak; Constantinos Petrovas; Alexandra Schuetz; Njabulo Ngwenyama; Gustavo Kijak; Leonard Maboko; Michael Hoelscher; Francine McCutchan; David A Price; Daniel C Douek; Richard A Koup
Journal:  Blood       Date:  2009-06-19       Impact factor: 22.113

3.  Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China.

Authors:  Tao Dong; Yonghong Zhang; Ke Yi Xu; Huiping Yan; Ian James; Yanchun Peng; Marie-Eve Blais; Silvana Gaudieri; Xinyue Chen; Wenhui Lun; Hao Wu; Wen Yan Qu; Tim Rostron; Ning Li; Yu Mao; Simon Mallal; Xiaoning Xu; Andrew McMichael; Mina John; Sarah L Rowland-Jones
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

4.  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Authors:  Mark J Geels; Sheri A Dubey; Kiersten Anderson; Elly Baan; Margreet Bakker; Georgios Pollakis; William A Paxton; John W Shiver; Jaap Goudsmit
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Higher homologous and lower cross-reactive Gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infection.

Authors:  Wim Jennes; Makhtar Camara; Tandakha Dièye; Souleymane Mboup; Luc Kestens
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.

Authors:  Hongtao Zhang; Raja Fayad; Xilin Wang; Daniel Quinn; Liang Qiao
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.

Authors:  Wing-Pui Kong; Yue Huang; Zhi-Yong Yang; Bimal K Chakrabarti; Zoe Moodie; Gary J Nabel
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

8.  T-cell immune responses against Env from CRF12_BF and subtype B HIV-1 show high clade-specificity that can be overridden by multiclade immunizations.

Authors:  Daniela C Mónaco; Ana M Rodríguez; María F Pascutti; Mauricio Carobene; Juliana Falivene; Alejandro Gómez; Cynthia Maeto; Gabriela Turk; José L Nájera; Mariano Esteban; M Magdalena Gherardi
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

9.  Unique CRF01_AE Gag CTL epitopes associated with lower HIV-viral load and delayed disease progression in a cohort of HIV-infected Thais.

Authors:  Masahiko Mori; Busarawan Sriwanthana; Nuanjun Wichukchinda; Chetsada Boonthimat; Naho Tsuchiya; Toshiyuki Miura; Panita Pathipvanich; Koya Ariyoshi; Pathom Sawanpanyalert
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

10.  Design and pre-clinical evaluation of a universal HIV-1 vaccine.

Authors:  Sven Létourneau; Eung-Jun Im; Tumelo Mashishi; Choechoe Brereton; Anne Bridgeman; Hongbing Yang; Lucy Dorrell; Tao Dong; Bette Korber; Andrew J McMichael; Tomás Hanke
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.